|
|
 |
|
|
|
|
20. J. Talafous, L. M. Sayre, J. J. Mieyal, and G. Klopman. META 2. A dictionary model of mammalian xenobiotic metabolism. J. Chem. Inf. Comput. Sci. 34: 13261333, 1994. |
|
|
|
|
|
|
|
|
21. M. Johnson. Assessing the reliability of methods for predicting drug metabolites. J. Biopharm. Stat. 1: 2756, 1991. |
|
|
|
|
|
|
|
|
22. C. Buchalter. Formula Searching in ISIS/Base. Scientist's Desktop. A Newsletter for ISIS and CPSS Scientific Software Users. 3:1, 1994. |
|
|
|
|
|
|
|
|
23. D. B. Campbell and N. Marchant. Specificity and variability in drug metabolism: An industrial point of view. Paper to be published in proceedings of Cost B1 European Conference on specificity and variability in drug metabolism. Besançon, 1012 May 1995. |
|
|
|
|
|
|
|
|
24. E. S. Vesell. On the significance of host factors that affect drug disposition. Clin. Pharmacol. Ther. 31: 17, 1982. |
|
|
|
|
|
|
|
|
25. A. K. Daly, S. Choleryon, W. Gregory, and J. R. Idel. Metabolic polymorphisms. Pharmacol. Ther. 57: 129160, 1993. |
|
|
|
|
|
|
|
|
26. U. M. Zanger, E.-U. Griese, B. Evert, and M. Eichelbaum. Function of the products of variant alleles for drug metabolising enzymes. Abstract L8. Paper to be published in proceedings of Cost B1 European Conference on specificity and variability in drug metabolism. Besançon, 1012 May 1995. |
|
|
|
|
|
|
|
|
27. R. Janeczko, D. J. Waxman, G. A. Le Blanc, A. Morville, and M. Adesnik. Hormonal regulation of levels of the messenger RNA encoding hepatic P450 2C (11C11), a constitutive male specific form of cytochrome P450. Molec. Endocrinol. 4: 295303, 1990. |
|
|
|
|
|
|
|
|
28. A. R. Boobis. Enzymatic studies in genetic polymorphisms of drug metabolism. In European cooperation in the field of scientific and technical research. G. Alvan, L. P. Balant, P. R. Bechter, A. R. Boobis, L. F. Gram, and K. Pithan, Eds. European Consensus Conference on Pharmacogenetics, Besançon, France, 2415 October 1990. Commission of the European Communities, Luxembourg, p. 1526. |
|
|
|
|
|
|
|
|
29. J. A. Bardsley. Establishment of human tissue banks. Human Exper. Toxicol. 13: 435437, 1994. |
|
|
|
|
|
|
|
|
30. D. R. Krishna and U. Klotz. Extrahepatic metabolism of drugs in humans. Clin. Pharmacokinetic. 26: 144160, 1994. |
|
|
|
|
|
|
|
|
31. M. F. Herbert, J. P. Roberts, T. Pracksaritanont, and L. Z. Benet. Bioavailability of cyclosporine with concomitant riampisin administration is markedly less than predicted by hepatic enzyme inhibition. Clin. Pharm. Ther. 52: 453457, 1992. |
|
|
|
|
|
|
|
|
32. W. Kalow. Pharmacogenetic variability in brain and muscle. J. Pharmac. Pharmacol. 46 (suppl 1): 425432, 1994. |
|
|
|
|
|
|
|
|
33. L. A. Siddoway, K. A. Thompson, C. B. McAllister, T. Wang, G. R. Wilkinson, et al. Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. Circulation 75: 785791, 1987. |
|
|
|
|
|
|
|
|
34. S. Sindrup, K. Brosen, and L. Gram. Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism. Clin. Pharm. Ther. 51: 288295, 1992. |
|
|
|
|
|
|
|
|
35. F. Macintyre, D. A. Smith, and P. E. Coates. Variability in human pharmacokinetics in volunteer studies and in the clinical situation. Abstract 25, 1996. Paper to be |
|
|
|
|
|